We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App





HORIBA Medical Launches HELO and Yumizen G Range

By LabMedica International staff writers
Posted on 05 Feb 2018
HORIBA Medical (Montpellier, France) showcased and launched the HELO island configuration solution and the new Yumizen G Range of coagulation analyzers at MEDLAB Middle East, the world’s largest attended laboratory and IVD exhibition and conference.
 
HORIBA Medical is one of the five segments of the Japanese HORIBA Group and one of the global leaders in the hematology market. More...
At the MEDLAB Middle East 2018 held from February 5-8, 2018 in Dubai, UAE, the company showcased HELO (HORIBA Evolutive Laboratory Organization), an innovative design solution covering all the needs of high throughput automated hematology platforms. The HELO solution is based on four fundamentals pillars: using reference methods to count cells, simplifying the user interface with its solution, consider tube workflow management differently from the competition and purpose a scalable solution to fit laboratory needs. With features such as high throughput of 120 samples per hour, automatic slide maker/stainer, comprehensive automated slide digitalization, automated conveyor with multi possible configurations, hematology middleware and expert validation station, HELO provides the optimum answer to the constant evolution of the laboratory.
 
HORIBA Medical also showcased the new Yumizen G Range of coagulation analyzers, which includes the Yumizen G1550, Yumizen G800, Yumizen G400, Yumizen G200 and Yumizen G100. The Yumizen G100 is the smallest analyzer for point of care laboratories to monitor oral anticoagulant, whereas the Yumizen G1550 is a fully automated, high-capacity coagulation analyzer to manage the diagnostic and monitoring requirements of clinical laboratories with mid to high workload. 
 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study validated a genetic scoring tool designed to help physicians diagnose idiopathic pulmonary fibrosis and stratify risk for severe outcomes, including death or lung transplantation (Image Credit: Adobe Stock)

Genetic Risk Score Supports Diagnosis and Prognosis in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) causes progressive, irreversible lung scarring that limits breathing and can lead to death. More than 100,000 Americans live with IPF, and an estimated 30,000–40,000... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Industry

view channel
Im

Eurobio Scientific Completes Acquisition of CareDx Lab Products Division

Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.